1
|
Barbarin A, Abdallah M, Lefèvre L, Piccirilli N, Cayssials E, Roy L, Gombert JM, Herbelin A. Innate T-αβ lymphocytes as new immunological components of anti-tumoral "off-target" effects of the tyrosine kinase inhibitor dasatinib. Sci Rep 2020; 10:3245. [PMID: 32094501 PMCID: PMC7039999 DOI: 10.1038/s41598-020-60195-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 02/03/2020] [Indexed: 12/31/2022] Open
Abstract
Kinase inhibitors hold great potential as targeted therapy against malignant cells. Among them, the tyrosine kinase inhibitor dasatinib is known for a number of clinically relevant off-target actions, attributed in part to effects on components of the immune system, especially conventional T-cells and natural killer (NK)-cells. Here, we have hypothesized that dasatinib also influences non-conventional T-αβ cell subsets known for their potential anti-tumoral properties, namely iNKT cells and the distinct new innate CD8 T-cell subset. In mice, where the two subsets were originally characterized, an activated state of iNKT cells associated with a shift toward an iNKT cell Th1-phenotype was observed after dasatinib treatment in vivo. Despite decreased frequency of the total memory CD8 T-cell compartment, the proportion of innate-memory CD8 T-cells and their IFNγ expression in response to an innate-like stimulation increased in response to dasatinib. Lastly, in patients administered with dasatinib for the treatment of BCR-ABL-positive leukemias, we provided the proof of concept that the kinase inhibitor also influences the two innate T-cell subsets in humans, as attested by their increased frequency in the peripheral blood. These data highlight the potential immunostimulatory capacity of dasatinib on innate T-αβ cells, thereby opening new opportunities for chemoimmunotherapy.
Collapse
Affiliation(s)
- Alice Barbarin
- INSERM, 1082, Poitiers, France.,CHU de Poitiers, Poitiers, France
| | | | | | | | - Emilie Cayssials
- INSERM, 1082, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Service d'Oncologie Hématologique de Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.,INSERM CIC-1402, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Lydia Roy
- Service Clinique d'Hématologie, Hôpital Henri-Mondor, Créteil, France.,Université Paris-Est Créteil, Créteil, France
| | - Jean-Marc Gombert
- INSERM, 1082, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| | - André Herbelin
- INSERM, 1082, Poitiers, France. .,CHU de Poitiers, Poitiers, France. .,Université de Poitiers, Poitiers, France.
| |
Collapse
|
2
|
Cayssials E, Jacomet F, Piccirilli N, Lefèvre L, Roy L, Guilhot F, Chomel JC, Leleu X, Gombert JM, Herbelin A, Barbarin A. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol 2019; 186:54-59. [PMID: 30864168 DOI: 10.1111/bjh.15858] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2019] [Accepted: 01/22/2019] [Indexed: 01/08/2023]
Abstract
Immunological mechanisms of treatment-free remission (TFR) in chronic myeloid leukaemia (CML) are poorly defined and, to date, no correlation between successful TFR and CD8(+) T-cell subsets has been found. We analysed a new identified human subset of CD8(+) T-cells, namely innate CD8(+) T-cells, in CML patients with TFR ≥ 2 years. We demonstrated a dramatic increase of functionally active innate CD8(+) T-cells in these patients as compared to control subjects and patients in remission under tyrosine kinase inhibitors. Moreover, we found a positive correlation between frequencies of innate CD8(+) T-cells and natural killer cells, possibly representing a new innate biomarker profile of successful TFR.
Collapse
Affiliation(s)
- Emilie Cayssials
- INSERM 1082, Poitiers, France.,Service d'Oncologie Hématologique de Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,CHU de Poitiers, Poitiers, France.,INSERM CIC-1402, Poitiers, France
| | - Florence Jacomet
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Service d'Immunologie et d'Inflammation, CHU de Poitiers, Poitiers, France
| | - Nathalie Piccirilli
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France.,CHU de Poitiers, Poitiers, France
| | - Lucie Lefèvre
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Lydia Roy
- Service Clinique d'Hématologie, Hôpital Henri-Mondor, Creteil, France.,Université Paris-Est Créteil, Creteil, France
| | - François Guilhot
- CHU de Poitiers, Poitiers, France.,INSERM CIC-1402, Poitiers, France
| | | | - Xavier Leleu
- Service d'Oncologie Hématologique de Thérapie Cellulaire, CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,CHU de Poitiers, Poitiers, France.,INSERM CIC-1402, Poitiers, France
| | - Jean-Marc Gombert
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France.,CHU de Poitiers, Poitiers, France.,INSERM CIC-1402, Poitiers, France.,Service d'Immunologie et d'Inflammation, CHU de Poitiers, Poitiers, France
| | - André Herbelin
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Alice Barbarin
- INSERM 1082, Poitiers, France.,Université de Poitiers, Poitiers, France
| |
Collapse
|
3
|
Evanno E, Godet J, Piccirilli N, Guilhot J, Milin S, Gombert JM, Fouchaq B, Roche J. Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clin Epigenetics 2017; 9:80. [PMID: 28804523 PMCID: PMC5549304 DOI: 10.1186/s13148-017-0380-0] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2016] [Accepted: 07/31/2017] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND The epithelial-to-mesenchymal transition (EMT) enables epithelial cancer cells to acquire mesenchymal features and contributes to metastasis and resistance to treatment. This process involves epigenetic reprogramming for gene expression. We explored global histone modifications during TGF-β1-induced EMT in two non-small cell lung cancer (NSCLC) cell lines and tested different epigenetic treatment to modulate or partially reverse EMT. RESULTS Loss of classical epithelial markers and gain of mesenchymal markers were verified in A549 and H358 cell lines during TGF-β1-induced EMT. In addition, we noticed increased expression of the axonal guidance protein semaphorin 3C (SEMA3C) and PD-L1 (programmed death-ligand 1) involved in the inhibition of the immune system, suggesting that both SEMA3C and PD-L1 could be the new markers of TGF-β1-induced EMT. H3K79me3 and H2BK120me1 were decreased in A549 and H358 cell lines after a 48-h TGF-β1 treatment, as well as H2BK120ac in A549 cells. However, decreased H3K79me3 was not associated with expression of the histone methyltransferase DOT1L. Furthermore, H3K79me3 was decreased in tumors compared in normal tissues and not associated with cell proliferation. Associations of histone deacetylase inhibitor (SAHA) with DOT1L inhibitors (EPZ5676 or SGC0946) or BET bromodomain inhibitor (PFI-1) were efficient to partially reverse TGF-β1 effects by decreasing expression of PD-L1, SEMA3C, and its receptor neuropilin-2 (NRP2) and by increasing epithelial markers such as E-cadherin. CONCLUSION Histone methylation was modified during EMT, and combination of epigenetic compounds with conventional or targeted chemotherapy might contribute to reduce metastasis and to enhance clinical responses.
Collapse
Affiliation(s)
- Emilie Evanno
- Eurofins Cerep SA, Le Bois l’Evêque, F-86600 Celle L’Evescault, France
- Université de Poitiers, Laboratoire LNEC, F-86022 Poitiers, France
| | - Julie Godet
- CHU de Poitiers, Service d’Anatomie et de Cytologie Pathologiques, F-86021 Poitiers, France
| | | | - Joëlle Guilhot
- INSERM CIC 0802, CHU de Poitiers, F-86021 Poitiers, France
| | - Serge Milin
- CHU de Poitiers, Service d’Anatomie et de Cytologie Pathologiques, F-86021 Poitiers, France
| | - Jean Marc Gombert
- INSERM U1082, CHU de Poitiers, F-86021 Poitiers, France
- Service Immunologie, CHU de Poitiers, F-86021 Poitiers, France
| | - Benoit Fouchaq
- Eurofins Cerep SA, Le Bois l’Evêque, F-86600 Celle L’Evescault, France
| | - Joëlle Roche
- Laboratoire Ecologie et Biologie des Interactions (EBI), Université de Poitiers, UMR-CNRS 7267, F-86073 Poitiers, France
| |
Collapse
|
4
|
Herbelin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefevre L, Abdallah M, Piccirilli N, Lavoue V, Catros V, Piaggio E, Gombert JM, Barbarin A. Eomesodermin together with KIR/NKG2A membrane receptors and CD49d as an useful strategy to identify NK-like CD8(+) T cells with innate features in humans: focusing on cancer diseases. The Journal of Immunology 2017. [DOI: 10.4049/jimmunol.198.supp.196.2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Abstract
Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells bear a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12+IL-18 stimulation. Although the concept of innate memory (IM) CD8(+) T cells is now well-established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12+IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans.
Here, we proposed Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Focusing on cancer diseases, we have provided new insights into the potential role of these IM CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we have observed both the possible contribution of IM CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we have investigated the involvement of IL-4 and IL-15 in the generation of the IM CD8(+) T cell pool and its dependency on promyelocytic leukemia zinc finger (PLZF)-expressing invariant Natural Killer T (iNKT) cells.
All in all, this study significantly contributes to understanding of the physiopathological role of NK-like CD8(+) T cells in humans and raises the question of the possible involvement of an iNKT/IM CD8(+) T cell axis in cancer.
Collapse
|
5
|
Barbarin A, Cayssials E, Jacomet F, Nunez NG, Basbous S, Lefèvre L, Abdallah M, Piccirilli N, Morin B, Lavoue V, Catros V, Piaggio E, Herbelin A, Gombert JM. Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases. Front Immunol 2017; 8:316. [PMID: 28396661 PMCID: PMC5366313 DOI: 10.3389/fimmu.2017.00316] [Citation(s) in RCA: 38] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 03/06/2017] [Indexed: 11/13/2022] Open
Abstract
Unconventional T cells are defined by their capacity to respond to signals other than the well-known complex of peptides and major histocompatibility complex proteins. Among the burgeoning family of unconventional T cells, innate-like CD8(+) T cells in the mouse were discovered in the early 2000s. This subset of CD8(+) T cells bears a memory phenotype without having encountered a foreign antigen and can respond to innate-like IL-12 + IL-18 stimulation. Although the concept of innate memory CD8(+) T cells is now well established in mice, whether an equivalent memory NK-like T-cell population exists in humans remains under debate. We recently reported that CD8(+) T cells responding to innate-like IL-12 + IL-18 stimulation and co-expressing the transcription factor Eomesodermin (Eomes) and KIR/NKG2A membrane receptors with a memory/EMRA phenotype may represent a new, functionally distinct innate T cell subset in humans. In this review, after a summary on the known innate CD8(+) T-cell features in the mouse, we propose Eomes together with KIR/NKG2A and CD49d as a signature to standardize the identification of this innate CD8(+) T-cell subset in humans. Next, we discuss IL-4 and IL-15 involvement in the generation of innate CD8(+) T cells and particularly its possible dependency on the promyelocytic leukemia zinc-finger factor expressing iNKT cells, an innate T cell subset well documented for its susceptibility to tumor immune subversion. After that, focusing on cancer diseases, we provide new insights into the potential role of these innate CD8(+) T cells in a physiopathological context in humans. Based on empirical data obtained in cases of chronic myeloid leukemia, a myeloproliferative syndrome controlled by the immune system, and in solid tumors, we observe both the possible contribution of innate CD8(+) T cells to cancer disease control and their susceptibility to tumor immune subversion. Finally, we note that during tumor progression, innate CD8(+) T lymphocytes could be controlled by immune checkpoints. This study significantly contributes to understanding of the role of NK-like CD8(+) T cells and raises the question of the possible involvement of an iNKT/innate CD8(+) T cell axis in cancer.
Collapse
Affiliation(s)
- Alice Barbarin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | - Emilie Cayssials
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Service d'Hématologie et d'Oncologie Biologique, CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Florence Jacomet
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| | - Nicolas Gonzalo Nunez
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - Sara Basbous
- INSERM 1082, Poitiers, France; Université de Poitiers, Poitiers, France
| | | | - Myriam Abdallah
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | | | | | - Vincent Lavoue
- INSERM U1242, Rennes, France; CHU de Rennes, Rennes, France
| | - Véronique Catros
- CHU de Rennes, Rennes, France; INSERM U991, Rennes, France; CRB Santé de Rennes, Rennes, France
| | - Eliane Piaggio
- Institut Curie, PSL Research University, INSERM U932, Paris, France; SiRIC Translational Immunotherapy Team, Translational Research Department, Research Center, Institut Curie, PSL Research University, Paris, France; Centre d'Investigation Clinique Biothérapie CICBT 1428, Institut Curie, Paris, France
| | - André Herbelin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Jean-Marc Gombert
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Immunologie et Inflammation, CHU de Poitiers, Poitiers, France
| |
Collapse
|
6
|
Jacomet F, Cayssials E, Barbarin A, Desmier D, Basbous S, Lefèvre L, Levescot A, Robin A, Piccirilli N, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM. The Hypothesis of the Human iNKT/Innate CD8(+) T-Cell Axis Applied to Cancer: Evidence for a Deficiency in Chronic Myeloid Leukemia. Front Immunol 2017; 7:688. [PMID: 28138330 PMCID: PMC5237805 DOI: 10.3389/fimmu.2016.00688] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2016] [Accepted: 12/23/2016] [Indexed: 01/16/2023] Open
Abstract
We recently identified a new human subset of NK-like [KIR/NKG2A(+)] CD8(+) T cells with a marked/memory phenotype, high Eomesodermin expression, potent antigen-independent cytotoxic activity, and the capacity to generate IFN-γ rapidly after exposure to pro-inflammatory cytokines. These features support the hypothesis that this new member of the innate T cell family in humans, hereafter referred to as innate CD8(+) T cells, has a role in cancer immune surveillance analogous to invariant natural killer T (iNKT) cells. Here, we report the first quantitative and functional analysis of innate CD8(+) T cells in a physiopathological context in humans, namely chronic myeloid leukemia (CML), a well-characterized myeloproliferative disorder. We have chosen CML based on our previous report that IL-4 production by iNKT cells was deficient in CML patients at diagnosis and considering the recent evidence in mice that IL-4 promotes the generation/differentiation of innate CD8(+) T cells. We found that the pool of innate CD8(+) T cells was severely reduced in the blood of CML patients at diagnosis. Moreover, like iNKT and NK cells, innate CD8(+) T cells were functionally impaired, as attested by their loss of antigen-independent cytotoxic activity and IFN-γ production in response to innate-like stimulation with IL-12 + IL-18. Remarkably, as previously reported for IL-4 production by iNKT cells, both quantitative and functional deficiencies of innate CD8(+) T cells were at least partially corrected in patients having achieved complete cytogenetic remission following tyrosine kinase inhibitor therapy. Finally, direct correlation between the functional potential of innate CD8(+) T and iNKT cells was found when considering all healthy donors and CML patients in diagnosis and remission, in accordance with the iNKT cell-dependent generation of innate CD8(+) T cells reported in mice. All in all, our data demonstrate that CML is associated with deficiencies of innate CD8(+) T cells that are restored upon remission, thereby suggesting their possible contribution to disease control. More generally, our study strongly supports the existence of an innate iNKT/innate CD8(+) T-cell axis in humans and reveals its potential contribution to the restoration of tumor immune surveillance.
Collapse
Affiliation(s)
- Florence Jacomet
- INSERM 1082, Poitiers, France; Service d'Immunologie et Inflammation, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Emilie Cayssials
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; Service d'Hématologie et d'Oncologie Biologique, Poitiers, France
| | - Alice Barbarin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | - Deborah Desmier
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Service d'Hématologie et d'Oncologie Biologique, Poitiers, France
| | - Sara Basbous
- INSERM 1082, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Lucie Lefèvre
- INSERM 1082, Poitiers, France; Université de Poitiers, Poitiers, France
| | | | - Aurélie Robin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France
| | | | - Christine Giraud
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Etablissement Français du Sang Centre-Atlantique, Site de Poitiers, Poitiers, France
| | - François Guilhot
- CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France; INSERM CIC-1402, Poitiers, France
| | - Lydia Roy
- INSERM CIC-1402, Poitiers, France; Service d'Hématologie Clinique, Hôpital Henri Mondor, Créteil, France; Université Paris-Est, Créteil, France
| | - André Herbelin
- INSERM 1082, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| | - Jean-Marc Gombert
- INSERM 1082, Poitiers, France; Service d'Immunologie et Inflammation, Poitiers, France; CHU de Poitiers, Poitiers, France; Université de Poitiers, Poitiers, France
| |
Collapse
|
7
|
Basbous S, Levescot A, Piccirilli N, Brizard F, Guilhot F, Roy L, Bourmeyster N, Gombert JM, Herbelin A. The Rho-ROCKpathway as a new pathological mechanism of innate immune subversion in chronic myeloid leukaemia. J Pathol 2016; 240:262-268. [DOI: 10.1002/path.4779] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/11/2016] [Revised: 07/20/2016] [Accepted: 08/03/2016] [Indexed: 11/05/2022]
Affiliation(s)
- Sara Basbous
- INSERM U1082; Poitiers France
- Université de Poitiers; Poitiers France
| | | | | | - Françoise Brizard
- CHU de Poitiers; Poitiers France
- Service d'Hématologie et d'Oncologie Biologique; Poitiers France
| | - François Guilhot
- Université de Poitiers; Poitiers France
- CHU de Poitiers; Poitiers France
- Service d'Hématologie et d'Oncologie Biologique; Poitiers France
- INSERM-CIC 1402; Poitiers France
| | | | | | - Jean-Marc Gombert
- INSERM U1082; Poitiers France
- Université de Poitiers; Poitiers France
- CHU de Poitiers; Poitiers France
- Service d'Immunologie et Inflammation; Poitiers France
| | - André Herbelin
- INSERM U1082; Poitiers France
- Université de Poitiers; Poitiers France
- CHU de Poitiers; Poitiers France
| |
Collapse
|
8
|
Jacomet F, Cayssials E, Basbous S, Levescot A, Piccirilli N, Desmier D, Robin A, Barra A, Giraud C, Guilhot F, Roy L, Herbelin A, Gombert JM. Evidence for eomesodermin-expressing innate-like CD8(+) KIR/NKG2A(+) T cells in human adults and cord blood samples. Eur J Immunol 2015; 45:1926-33. [PMID: 25903796 DOI: 10.1002/eji.201545539] [Citation(s) in RCA: 83] [Impact Index Per Article: 9.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2015] [Revised: 03/25/2015] [Accepted: 04/20/2015] [Indexed: 12/31/2022]
Abstract
Polyclonal CD8(+) T cells, with a marked innate/memory phenotype, high eomesodermin (Eomes) expression, and the capacity to generate IFN-γ rapidly without prior exposure to antigen, have been described in mice. However, even though a pool of human CD8(+) T cells expressing killer Ig-like receptors (KIRs) was recently documented, the existence of a human equivalent of murine innate/memory CD8(+) T cells remains to be established. Here, we provide evidence for a population of KIR/NKG2A(+) CD8(+) T cells in healthy human adults sharing the same features, namely increased Eomes expression, prompt IFN-γ production in response to innate-like stimulation by IL-12+IL-18, and a potent antigen-independent cytotoxic activity along with a preferential terminally differentiated effector memory phenotype. None of the above functional characteristics applied to the KIR/NKG2A(-) fraction of the Eomes(+) CD8(+) T-cell population, thereby underlining the ability of KIR/NKG2A to distinguish between "innate/memory-like" and "conventional/memory" pools of CD8(+) T cells. Remarkably, KIR/NKG2A(+) Eomes(+) CD8(+) T cells with innate-like functions and a memory/terminally differentiated effector memory phenotype were also identified in human cord blood, suggesting that their development did not depend on cognate antigens. Taken together, our results support the conclusion that CD8(+) T cells co-expressing Eomes and KIR/NKG2A may represent a new, functionally distinct "innate/memory-like" subset in humans.
Collapse
Affiliation(s)
- Florence Jacomet
- INSERM UMR S935, Poitiers and Villejuif, France.,Service d'Immunologie et Inflammation, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Emilie Cayssials
- INSERM UMR S935, Poitiers and Villejuif, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Sara Basbous
- INSERM UMR S935, Poitiers and Villejuif, France.,Université de Poitiers, Poitiers, France
| | - Anaïs Levescot
- INSERM UMR S935, Poitiers and Villejuif, France.,Université Paris-Sud 11, Orsay, France.,INSERM 1082, Poitiers, France
| | | | - Deborah Desmier
- INSERM UMR S935, Poitiers and Villejuif, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Aurélie Robin
- CHU de Poitiers, Poitiers, France.,INSERM 1082, Poitiers, France
| | - Anne Barra
- INSERM UMR S935, Poitiers and Villejuif, France.,Service d'Immunologie et Inflammation, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France
| | - Christine Giraud
- INSERM UMR S935, Poitiers and Villejuif, France.,CHU de Poitiers, Poitiers, France.,Etablissement Français du Sang Centre-Atlantique, Site de Poitiers, Poitiers, France
| | - François Guilhot
- CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,Centre d'investigation clinique INSERM-1402, Poitiers, France.,Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | - Lydia Roy
- CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,Centre d'investigation clinique INSERM-1402, Poitiers, France.,Service d'Oncologie Hématologique et Thérapie Cellulaire, Poitiers, France
| | - André Herbelin
- CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France.,INSERM 1082, Poitiers, France
| | - Jean-Marc Gombert
- INSERM UMR S935, Poitiers and Villejuif, France.,Service d'Immunologie et Inflammation, Poitiers, France.,CHU de Poitiers, Poitiers, France.,Université de Poitiers, Poitiers, France
| |
Collapse
|